Prime Medicine, Inc. Common Stock (PRME) is a publicly traded Healthcare sector company. As of July 8, 2026, PRME trades at $4.50 with a market cap of $720.66M and a P/E ratio of -3.18. PRME moved +11.15% today. Year to date, PRME is +15.99%; over the trailing twelve months it is +5.00%. Its 52-week range spans $1.11 to $6.94. Analyst consensus is strong buy with an average price target of $7.83. Rallies surfaces PRME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Prime Medicine Wins Arbitration, Secures PM647 Rights and Plans Q3 2026 IND: An arbitral tribunal ruled PM647 falls within Prime Medicine’s licensed field, confirming their right to develop and commercialize the AATD therapy without owing damages to Beam Therapeutics. The company will submit an IND/CTA for PM647 in Q3 2026 and expects initial clinical data in 2027.
| Metric | Value |
|---|---|
| Price | $4.50 |
| Market Cap | $720.66M |
| P/E Ratio | -3.18 |
| EPS | $-1.25 |
| Dividend Yield | 0.80% |
| 52-Week High | $6.94 |
| 52-Week Low | $1.11 |
| Volume | 5.41M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.03M |
| Net Income | $-198.37M |
| Gross Margin | 0.00% |
8 analysts cover PRME: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.83.